PITTSBURGH 2019

Hungary:
Pancreatitis Working Groups and Resources

Péter Hegyi
Andrea Párniczky
Balázs Németh

TM TRANSLATIONAL MEDICINE

TM 2011-2019

HUNGARIAN PANCREATIC STUDY GROUP

TRANSLATIONAL MEDICINE

taking discoveries for patients benefits

TRANSZLÁCIÓS MEDICINA

HEALTH CARE

QUESTION

PRACTICE

SCIENCE

BASIC SCIENCE PURE FUNDAMENTAL RESEARCH	APPLIED SCIENCE DEVELOP KNOWLEDE FOR PRACTICAL APPLICATION	CLINICAL SCIENCE PRACTICAL APPLICATION
DISCOVERING NEW MECHANISMS AND TARGETS	DEVELOPING NEW DRUGS AND INTERVENTIONS	UNDERSTANDING SAFTEY AND EFFECTIVENESS
MOLECULAR BIOLOGY CELLULAR IMAGING PHYSIOLOGY	PHARMACOLOGY DEVICE D. INTERVENTIONAL D.	META-ANALYSIS INTERVENTIONAL CT OBSERVATIONAL CT PROSPECTIVE DA RETROSPECTIVE DA

TRANSZLÁCIÓS MEDICINA Pécs

EDUCATION
GRADUATE AND POSTGRADUATE EDUCATION, PATIENT CLUBS
DISSEMINATION OF INFORMATION

- FOR PROFESSIONALS
- FOR NON-PROFESSIONALS

EDUCATION

SCEINTIFIC PUBLICATION

KNOWLEDGE PUBLICATION

KNOWLEDGE

TRANSLATIONAL MEDICINE

taking discoveries for patients benefits

HUNGARIAN PANCREATIC STUDY GROUP

TRANSZLÁCIÓS MEDICINA



University of Pécs
Centre for TRANSLATIONAL MEDICINE

www.tm-centre.org

TRANSLATIONAL MEDICINE

taking discoveries for patients benefits

TRANSZLÁCIÓS MEDICINA



TRANSLATIONAL MEDICINE

taking discoveries for patients benefits

TRANSZLÁCIÓS MEDICINA

	2016 Jan	2016 Sep	2017 Feb	2017 Sep és 2018 Jan	
	ROUND I.	**ROUND II.**	**ROUND III.**	**ROUND V**	**SUMMARY**
PUBLISHED	13	14	3	4	**34**
ACCEPTED	0	1	1	0	**2**
SUBMITTED	2	3	2	8	**15**
IN PREPARATION	0	8	6	28	**42**
	15	**26**	**12**	**40**	**93**

Q1	**31**
Q2	**4**
Q3	**0**
Q4	**0**
Data updated	**2018.12.25**



TRANSLATIONAL MEDICINE

taking discoveries for patients benefits

TRANSZLÁCIÓS MEDICINA

TRANSLATIONAL MEDICINE

taking discoveries for patients benefits

TRANSZLÁCIÓS MEDICINA





TRANSLATIONAL MEDICINE

taking discoveries for patients benefits

TM TRANSZLÁCIÓS MEDICINA

CENTRAL INTERDISCIPLINARY UNIT

TM CENTRAL INTERDISCIPLINARY UNIT
for better healthcare

MEDICAL GROUP
COORDINATORS

DATA MANAGEMENT GROUP
STATISTICAL GROUP
IT GROUP

HEALTH ECONOMICS GROUP
MEDIA GROUP
PATIENT CLUB COORDINATOR
HR AND FINANCIAL GROUP

2019

TRANSLATIONAL MEDICINE

taking discoveries for patients benefits

University of Pécs
Centre for TRANSLATIONAL MEDICINE

HUNGARIAN PANCREATIC STUDY GROUP

WORKING GROUPS

ADULT (AP – CP) PANCREATITIS

Péter Hegyi

PEDIATRIC PANCREATITIS

Andrea Párniczky

GENETICS

Balázs Németh

HUNGARIAN PANCREATIC STUDY GROUP

WORKING GROUPS

ADULT (AP – CP) PANCREATITIS

Péter Hegyi

TRANSLATIONAL MEDICINE
Meta-Analysis

10

frontiers in Physiology

SYSTEMATIC REVIEW
published: 02 April 2019
doi: 10.3389/fphys.2019.00328

frontiers in Physiology

ORIGINAL RESEARCH
published: 01 October 2018
doi: 10.3389/fphys.2018.01360

www.nature.com/scientificreports

Recei
Accep
Publi

Toh

Sana Klinik

ORIGINAL ARTICLE

OPEN

Pancreatitis-Associated Genes and Pancreatic Cancer Risk

A Systematic Review and Meta-analysis

Irina Mihaela Cazacu, MD,† Nelli Farkas, PhD,‡ András Garami, MD, PhD,* Márta Balaskó, MD, PhD,* Bernadett Mosdósi, MD, PhD,§ Hussain Alizadeh, MD, PhD,|| Zoltán Gyöngyi, MD, PhD,¶ Zoltán Rakonczay, Jr, MD, PhD,# Éva Vigh, MD,** Tamás Habon, MD, PhD,†† László Czopf, MD, PhD,†† Marilena Alina Lazarescu, MD,* Bálint Erőss, MD, PhD,* Miklós Sahin-Tóth, MD, PhD,‡‡ and Péter Hegyi, MD, PhD, DSc(Med)§§||||*

Objective: The aim of this study was to evaluate the connection between pancreatic cancer (PC) and genetic variants associated with chronic pancreatitis via systematic review and meta-analysis.

Methods: The data search was performed in 3 major databases (PubMed, Embase, and Cochrane Library). The selected studies have looked into the presence of the pancreatitis-associated genes in patients with PC and in control subjects, the outcome being the frequency of the mutations in the 2 groups. For the binary outcomes, pooled odds ratio (OR) and 95% con-

Key Words: chronic pancreatitis, *CFTR*, pancreatic cancer, *SPINK1*

(*Pancreas* 2018;47: 1078–1086)

Pancreatic cancer (PC) is one of the most lethal and therapeutically resistant malignancies, with a grim prognosis that is related to the late clinical presentation and the rapid progression of the disease. Despite extensive research, the etiology and pathomechanism remain

TRANSLATIONAL MEDICINE

taking discoveries for patients benefits

University of Pécs
Centre for TRANSLATIONAL MEDICINE

TRANSLATIONAL MEDICINE Trials

9

Original Paper

Open Access Protocol

BMJ Open

Open access Protocol

BMJ Open

Endoscopic sphincterotoMy for delayIng choLecystectomy in mild acute biliarY pancreatitis (EMILY study): protocol of a multicentre randomised clinical trial

Levente Pál Kucserik,[1] Katalin Márta,[2,3] Áron Vincze,[2,4] György Lázár,[5] László Czakó,[6] Zsolt Szentkereszty,[7] Mária Papp,[8] Károly Palatka,[8] Ferenc Izbéki,[9] Áron Altorjay,[10] Imola Török,[11] Sorin Barbu,[12] Marcel Tantau,[12] András Vereczkei,[13] Lajos Bogár,[14] Márton Dénes,[15] Imola Németh,[16] Andrea Szentesi,[17,18] Noémi Zádori,[2] Judit Antal,[2] Markus M Lerch,[19] John Neoptolemos,[20] Miklós Sahin-Tóth,[21] Ole H Petersen,[22] Dezső Kelemen,[23] Péter Hegyi[2,24]

To cite: Márta K, Szabó AN, Pécsi D, *et al*. High versus low energy administration in the early phase of acute pancreatitis (GOULASH trial): protocol of a multicentre randomised double-blind clinical trial. *BMJ Open* 2017;**7**:e015874. doi:10.1136/bmjopen-2017-015874

To cite: Kucserik LP, Márta K, Vincze Á, *et al*. Endoscopic sphincterotoMy for delayIng choLecystectomy in mild acute biliarY pancreatitis (EMILY study): protocol of a multicentre randomised clinical trial. *BMJ Open* 2019;**9**:e025551. doi:10.1136/bmjopen-2018-025551

ABSTRACT

Introduction According to the literature, early cholecystectomy is necessary to avoid complications related to gallstones after an initial episode of acute biliary pancreatitis (ABP). A randomised, controlled multicentre trial (the PONCHO trial) revealed that in the case of gallstone-induced pancreatitis, early cholecystectomy was safe in patients with mild gallstone pancreatitis and reduced the risk of recurrent gallstone-related

Strengths and limitations of this study

- The study is designed as a prospective, randomised-controlled trial to achieve conclusion on the highest evidence level to provide the first evidence concerning the possible benefits of sphincterotomy (ES) on timing cholecystectomy, it is (i) multinational, (ii) multicentric, (iii) internationally registered and (iv) the prestudy protocol is published

TRANSLATIONAL MEDICINE

taking discoveries for patients benefits

University of Pécs Centre for TRANSLATIONAL MEDICINE

TM PANCREAS REGISTRIES
PANCREATIC STUDY GROUP

12

G Model
YDLD-4042; No. of Pages 6

ARTICLE IN PRESS

Digestive and Liver Disease xxx (2019) xxx–xxx

ELS

Dige

Out
cho

Adri
Rola
Áro
Balá
Barr
Bálii

[a] Szent
[b] Institu
[c] Institu
[d] Bajcsy
[e] First I
[f] First I
[g] Heim
[h] BMK
[i] BMKK
[j] Bács-
[k] Dr. Bu
[l] Marku
[m] First
[n] MTA-

frontiers in Ph

PLOS ONE

CrossMark
click for updates

OPEN ACCESS

Citation: Párniczky A, Kui B, Szentesi A, Bá
Szücs Á, Mosztbacher D, et al. (2016) Pros
Multicentre, Nationwide Clinical Data from
Cases of Acute Pancreatitis. PLoS ONE 11
e0165309. doi:10.1371/journal.pone.0165

ORIGINAL RESEARCH

Pancreatology xxx (xxxx) xxx-xxx

Contents lists available at ScienceDirect

Pancreatology

journal homepage: www.elsevier.com

ELSEVIER

Antibiotic therapy in acute pancreatitis: From global overuse to evidence based recommendations

Andrea Párniczky [a, b, 1], Tamás Lantos [c, 1], Eszter Margit Tóth [d, e, 1], Zsolt Szakács [a], Szilárd Gódi [f], Roland Hágendorn [g], Dóra Illés [e], Balázs Koncz [e], Katalin Márta [a], Alexandra Mikó [h], Dóra Mosztbacher [a, i], Balázs Csaba Németh [e], Dániel Pécsi [a], Anikó Szabó [a], Ákos Szücs [j], Péter Varjú [a], Andrea Szentesi [a, e], Erika Darvasi [e], Bálint Erőss [a], Ferenc Izbéki [k], László Gajdán [k], Adrienn Halász [k], Áron Vincze [f], Imre Szabó [f], Gabriella Pár [f], Judit Bajor [f], Patrícia Sarlós [f], József Czimmer [f], József Hamvas [l], Tamás Takács [e], Zoltán Szepes [e], László Czakó [e], Márta Varga [m], János Novák [d], Barnabás Bod [n], Attila Szepes [o], János Sümegi [p], Mária Papp [q], Csaba Góg [r], Imola Török [s], Wei Huang [t], Qing Xia [t], Ping Xue [u], Weiqin Li [v], Weiwei Chen [w], Natalia V. Shirinskaya [x], Vladimir L. Poluektov [y], Anna V. Shirinskaya [y], Péter J. Hegyi [a, z], Marian Bátovský [z], Juan Armando Rodriguez-Oballe [aa], Isabel Miguel Salas [aa], Javier Lopez-Diaz [ab], J. Enrique Dominguez-Munoz [ab], Xavier Molero [ac], Elizabeth Pando [ad], María Lourdes Ruiz-Rebollo [ae], Beatriz Burgueño-Gómez [ae], Yu-Ting Chang [af], Ming-Chu Chang [af], Ajay Sud [ag], Danielle Moore [ag], Robert Sutton [ag], Amir Gougol [ah], Georgios I. Papachristou [ah], Yaroslav Mykhailovych Susak [ai], Illia Olehovych Tiuliukin [ai], Antonio Pedro Gomes [aj], Maria Jesus Oliveira [aj], David João Aparício [aj], Marcel Tantau [ak], Floreta Kurti [al], Mila Kovacheva-Slavova [am], Stephanie-Susanne Stecher [an], Julia Mayerle [an], Goran Poropat [ao], Kshaunish Das [ap], Marco Vito Marino [aq], Gabriele Capurso [ar], Ewa Małecka-Panas [as], Hubert Zatorski [as], Anita Gasiorowska [at], Natalia Fabisiak [at], Piotr Ceranowicz [au], Beata Kuśnierz-Cabala [au], Joana Rita Carvalho [av], Samuel Raimundo Fernandes [av], Jae Hyuck Chang [aw], Eun Kwang Choi [ax], Jimin Han [ay], Sara Bertilsson [az, ba], Hanaz Jumaa [bb], Gabriel Sandblom [bc], Sabite Kacar [bd], Minas Baltatzis [be], Aliaksandr Vladimir Varabei [bf], Vizhynis Yeshy [bg], Serge Chooklin [bh], Andriy Kozachenko [bi]

PROOF

TRANSLATIONAL MEDICINE

taking discoveries for patients benefits

HUNGARIAN PANCREATIC STUDY GROUP

TRANSZLÁCIÓS MEDICINA



There is a general overuse of AB in AP

23 countries

63 centres

[illegible]ts

[illegible]7%

Spain:	31.8%
Sweden:	32.6%
Germany	34.9%

Albania:	81.7%
South Korea:	89.3%
Taiwan	80.6%



Elevated CRP level, WBC count, lipase and amylase levels are the biomarkers used for the initiation of AB therapy

TRANSLATIONAL MEDICINE

taking discoveries for patients benefits

HUNGARIAN PANCREATIC STUDY GROUP

TRANSZLÁCIÓS MEDICINA

	LAB	START OF AB THERAPY Day1	Day2	Day3	Day4
3	8,1 ± 0,4	72,5%	10,0%	8,3%	9,2%
4a	7,9 ± 0,2	74,0%	11,7%	5,5%	8,8%
4b	13,1 ± 1,3	76,5%	6,9%	6,9%	
5	16,2 ± 1,5	72,4%	10,5%		
AB	9,6 ± 3	74,0%			

3				16,2%
				54,4%
			16,3%	14,7%
		10,5%	7,0%	14,7%
		100%	100%	100%

100%

90% of AB therapy started in the first 3 days ofAP

Pancreatic infection causes the worst outcome in AP.



ONLY

PANCREAS

BILIARY

RESPIRATORY

UROGENITALY

OTHER

COMBINED

severity

mortality



TRANSLATIONAL MEDICINE

taking discoveries for patients benefits

HUNGARIAN PANCREATIC STUDY GROUP

TRANSZLÁCIÓS MEDICINA

	%
1	12,7%
2	12,7%
noAB	25,4%
3	12,5%
4a	43,7%
4b	10,6%
5	7,9%
AB	74,6%

N = 962 p

PREVENTIVE
EMPIRIC
NEG BACT
POS BAC

CRP





Elevation of CRP, WBC, lipase or amylase levels are NOT associated with infection in the early phase of AP







Pancreatology 19 (2019) 488–499

Contents lists available at ScienceDirect

Pancreatology

journal homepage: www.elsevier.com/locate/pan

OPEN ACCESS

Antibiotic therapy in acute pancreatitis: From global overuse to evidence based recommendations

Andrea Párniczky [a, b, 1], Tamás Lantos [c, 1], Eszter Margit Tóth [d, e, 1], Zsolt Szakács [a], Szilárd Gódi [f], Roland Hágendorn [g], Dóra Illés [e], Balázs Koncz [e], Katalin Márta [a], Alexandra Mikó [a, h], Dóra Mosztbacher [a, i], Balázs Csaba Németh [e, bk], Dániel Pécsi [a], Anikó Szabó [a], Ákos Szücs [j], Péter Varjú [e], Andrea Szentesi [a, e], Erika Darvasi [e], Bálint Erőss [a], Ferenc Izbéki [k], László Gajdán [k], Adrienn Halász [k], Áron Vincze [f], Imre Szabó [f], Gabriella Pár [f], Judit Bajor [f], Patrícia Sarlós [f], József Czimmer [f], József Hamvas [l], Tamás Takács [l], Zoltán Szepes [e], László Czakó [e], Márta Varga [m], János Novák [d], Barnabás Bod [n], Attila Szepes [o], János Sümegi [p], Mária Papp [q], Csaba Góg [r], Imola Török [s], Wei Huang [t], Qing Xia [t], Ping Xue [u], Weiqin Li [v], Weiwei Chen [w], Natalia V. Shirinskaya [x], Vladimir L. Poluektov [y], Anna V. Shirinskaya [y], Péter Jenő Hegyi [a, z], Marian Bátovský [z], Juan Armando Rodriguez-Oballe [aa], Isabel Miguel Salas [aa], Javier Lopez-Diaz [ab], J. Enrique Dominguez-Munoz [ab], Xavier Molero [ac], Elizabeth Pando [ad], María Lourdes Ruiz-Rebollo [ae], Beatriz Burgueño-Gómez [ae], Yu-Ting Chang [af], Ming-Chu Chang [af], Ajay Sud [ag], Danielle Moore [ag], Robert Sutton [ag], Amir Gougol [ah], Georgios I. Papachristou [ah],



HUNGARIAN PANCREATIC STUDY GROUP

WORKING GROUPS

PEDIATRIC PANCREATITIS

Andrea Párniczky

Hungarian Pancreatic Study Group 2011-2019



TRANSLATIONAL MEDICINE

taking discoveries for patients benefits

TRANSZLÁCIÓS MEDICINA

TM PEDIATRICS

HUNGARIAN PANCREATIC STUDY GROUP

5

ÖSSZEFOGLALÓ KÖZLEMÉNY

Digestion

A

Pá

Kelen
Sah
S

Sze
2]

7Pé

10Depart

Analysi
(APPLE
Multina

Andrea Párnic
Natália Lásztit
Group and the

a1st Department of
Group, and bDepart
dBalassa János Hosp
Medical University,

Original Paper

Pancreatology 18 (2018) 146–160

Contents lists available at ScienceDirect

Pancreatology

journal homepage: www.elsevier.com/locate/pan

EPC/HPSG evidence-based guidelines for the management of pediatric pancreatitis

Andrea Párniczky [a, b], Maisam Abu-El-Haija [c], Sohail Husain [d], Mark Lowe [e], Grzegorz Oracz [f], Miklós Sahin-Tóth [g], Flóra K. Szabó [h], Aliye Uc [i], Michael Wilschanski [j], Heiko Witt [k], László Czakó [l], Tassos Grammatikopoulos [m, n], Ib Christian Rasmussen [o], Robert Sutton [p, q], Péter Hegyi [b, l, *]

[a] Heim Pál Children's Hospital, Budapest, Hungary
[b] Institute for Translational Medicine, University of Pécs, Pécs, Hungary
[c] Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
[d] Department of Pediatrics, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, PA, USA
[e] Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA
[f] Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The Children's Memorial Health Institute, Warsaw, Poland
[g] Department of Molecular and Cell Biology, Center for Exocrine Disorders, Boston University Henry M. Goldman School of Dental Medicine, Boston, MA, USA
[h] Division of Gastroenterology and Nutrition, Children's Hospital of Richmond, Virginia Commonwealth University, Richmond, VA, USA
[i] Division of Pediatric Gastroenterology, Stead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA, USA
[j] Pediatric Gastroenterology Unit, Hadassah Hebrew University Hospital, Jerusalem, Israel
[k] Else Kröner-Fresenius-Zentrum für Ernährungsmedizin, Paediatric Nutritional Medicine, Technische Universität München, Freising, Germany
[l] First Department of Medicine, University of Szeged, Szeged, Hungary
[m] Paediatric Liver, GI & Nutrition Centre, King's College Hospital, London, United Kingdom
[n] Institute of Liver Studies, Division of Transplantation Immunology and Mucosal Biology, King's College London, London, United Kingdom

Pain IN the Early phase of Pediatric Pancreatitis

ISRCTN:	**89664974**
Start of trial:	**February, 2015**
Expected closure:	**March, 2020**
Enrolled patients:	
PINEAPPLE-R:	**46190**
PINEAPPLE-P:	**790**
Number of centre:	**10**

TM PINEAPPLE
HUNGARIAN PANCREATIC STUDY GROUP

Pain in the Early Phase of Pediatric Pancreatitis
PINEAPPLE

PINEAPPLE-R

n= 46190

				
	n=6419	n=11733	n=15484	n=12554
Abdominal pain	4.1%	6%	11%	16%
Abdominal imaging	41.6%	28%	39%	6%
Amylase/lipase	63%	22%	13%	5%
ACUTE PANCREATITIS	1.1% (n=3)	0.5% (n=4)	0,2% (n=4)	0% (n=0)

r^2= 0,96

PINEAPPLE-P

CURRENT PRACTICE		EVIDENCE
PINEAPPLE-R (n= 46190)		APPLE-P (n=790)
23%	INAL US	100%
1	REATIC ENZYME MEASUREMENT	100%
0.2%	10X	2.3%

NEW CENTERS ARE WELCOME

Analysis of Pediatric Pancreatitis

ISRCTN: 89664974

Start of trial: February, 2015

Expected closure: March, 2020

Enrolled patients:

- **APPLE-R:** 164
- **APPLE-P:** 79

Number of centrum: 16

TM APPLE
HUNGARIAN PANCREATIC STUDY GROUP

Analysis of Pediatric Pancreatitis
APPLE

Therapeutic strategy

Evidence-based guidelines should be followed strictly in order to reduce the length of hospitalization in APP





TRANSLATIONAL MEDICINE

taking discoveries for patients benefits

	with genetic risk (n=59)	all patients (n=121)
PRSS1	6.8%	2.5%
CFTR	25,4%	12,4%

Pathogenic variants were identi… 63% of idiopathic cases and in 34% of non-idio… …ses.

Pathogenic vari… …e found in 32% of AP, 65% of ARP, 80% of CP …

NEW CENTERS ARE WELCOME



HUNGARIAN PANCREATIC STUDY GROUP

WORKING GROUPS

GENETICS

Balázs Németh

Genetic testing in Hungary for patients with pancreatitis

Children

1. **acute / recurrent acute / chronic pancreatitis**

2. testing is **independent from etiology**

3. **pancreatitis under 19** years of age
   at the time of diagnosis
   independent from actual age

TM APPLE
HUNGARIAN PANCREATIC STUDY GROUP

Adults

1. **recurrent acute pancreatitis**
   at least 2 acute episodes

2. **chronic pancreatitis**

3. **pancreatitis** under 35 years of age
   at the time of diagnosis
   independent from actual age

4. **Etiology is unknown (IDIOPATHIC)**

Genetic testing in Hungary for patients with pancreatitis

TM GENETICS
HUNGARIAN PANCREATIC STUDY GROUP

MIKLÓS SAHIN-TÓTH

12

PostScript

LETTER

Novel p.
causes n
hereditar
autosom
dominan

We read th
al[1] with gre
that the m
tive carbox
tions can
to nonsens
therefore,
reported Ci
chronic pa
ing-depend
ingly offere
finding of
reported n
functionall
large Chine
However
functionall
CPA1 gen
with spor

A

Author Manuscript

Author Manuscript

Author Manuscript

HHS Public Access

Author manuscript

Am J Gastroenterol. Author manuscript; available in PMC 2018 June 01.

Published in final edited form as:

Am J Gastroenterol. 2017 December ; 112(12): 1896–1898. doi:10.1038/ajg.2017.393.

Novel *PRSS1* mutation p.P17T validates pathogenic relevance of CTRC-mediated processing of the trypsinogen activation peptide in chronic pancreatitis

Balázs Csaba Németh[1,2], **Ákos Szücs**[3], **Péter Hegyi**[4,5,*], and **Miklós Sahin-Tóth**[1,*]

[1]Center for Exocrine Disorders, Department of Molecular and Cell Biology, Boston University Henry M. Goldman School of Dental Medicine, Boston, MA 02118

[2]First Department of Medicine, University of Szeged, Szeged, Hungary

[3]First Department of Surgery, Semmelweis University, Budapest, Hungary

[4]Institute for Translational Medicine and First Department of Medicine, University of Pécs, Pécs, Hungary

[5]MTA-SZTE Translational Gastroenterology Research Group, Szeged, Hungary

To the editor

Mutations in *PRSS1* cause hereditary pancreatitis by reducing chymotrypsin C (CTRC)-



121 patients with childhood-onset pancreatitis were tested

	Percentage of mutation carriers in patients
PRSS1	2.5%
CTRC	37.3%
SPINK1	9.9%
CPA1	2.5%
CFTR	12.4%

Etiology



No mutation



CTRC

- idiopathic
- biliary
- alcoholic
- anatomy
- virus
- drug
- IBD
- hyperlipidaemia

Type of pancreatitis



No mutation



CTRC

- Acute pancreatitis
- Recurrent acute pancreatitis
- Chronic pancreatitis

AP / (RAP+ CP) → p = 0.03

PRSS1 p.P17T mutation
In a case of childhood onset chronic pancreatitis







Németh BC, Szücs Á, Hegyi P, Sahin-Tóth M.

Novel PRSS1 Mutation p.P17T Validates Pathogenic Relevance of CTRC-Mediated Processing of the Trypsinogen Activation Peptide in Chronic Pancreatitis.

Am J Gastroenterol. 2017 Dec;112(12):1896-1898

EPC - BERGEN

TRANSLATIONAL MEDICINE

taking discoveries for patients benefits

University of Pécs
Centre for TRANSLATIONAL MEDICINE

2011: 13 abstracts

HUNGARY

2019: 57 abstracts



PARIS 2020 • BERLIN 2018 • BUDAPEST 2017
E·P·C
BERGEN 2019

Thank you for your attention!

TM HUNGARIAN PANCREATIC STUDY GROUP

The Hungarian Pancreatic Study Group is committed to improving the lives of patients suffering from pancreatic diseases!

TM TRANSLATIONAL MEDICINE Basic Science

TM TRANSLATIONAL MEDICINE Trials

www.pancreas.hu